Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis

Table 3 Kidney function before and after treatment

Study	No. of patients	Mean/Median eGFR (mL/min/1. 73m²)/ Serum Creatinine (mg/dL) at baseline	Mean/Median eGFR (mL/min/1. 73m²)/ Serum Creatinine (mg/dL) after treatment	P-value/Comments from investigator
Dumortier (2017) [18]	15 non-HD patients	eGFR 29.0 (20–34)	eGFR 27.0 (17–38)	In non-HD patients, median eGFR was not significantly modified during treatment.
Taneja (2018) [22]	11 pre-dialysis patients	eGFR 24.84 ± 3.96	eGFR 24.39 ± 3.63	0.82
Taneja (2018) [22]	11 pre-dialysis patients	Creatinine2.52 ± 0.35	Creatinine 2.56 ± 0.36	0.81
Singh(2017) [34]	36	eGFR 12.02 ± 6.89	eGFR 12.33 ± 6.10	0.77
Cox-North (2017) [35]	NA patients not receiving dialysis	eGFR 22.2 creatinine 3.1	eGFR 20 creatinine 3.3	1.0

ISSN: 1743-422X